
## **Dmitry Belousov**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3431960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU). , 2022, 2, 1-9.		7
2	Chinese experience on using RWE to support drug research, development and evaluation. , 2022, 2, 17-27.		1
3	Bioethical Aspects of Translational Medicine. Kutafin Law Review, 2022, 9, 175-190.	0.1	0
4	3D bioprinting: issues of bioethics. , 2022, , .		0
5	Socioeconomic and global burden of COVID-19. Kachestvennaya Klinicheskaya Praktika, 2021, 20, 24-34.	0.2	6
6	Ethical aspects of using software with artificial intelligence technology. Kachestvennaya Klinicheskaya Praktika, 2021, 20, 70-84.	0.2	2
7	Review of real-world data study. Kachestvennaya Klinicheskaya Praktika, 2021, 20, 56-63.	0.2	6
8	Ethical aspects of the Internet of Bodies. Kachestvennaya Klinicheskaya Praktika, 2021, , 89-98.	0.2	1
9	Clinical and economic aspects of the use of OneTouch glucose meters for the screening of diabetes mellitus. Kachestvennaya Klinicheskaya Praktika, 2021, , 73-81.	0.2	0
10	Socio-economic burden of COVID-19 in the Russian Federation. Kachestvennaya Klinicheskaya Praktika, 2020, , 35-44.	0.2	7
11	PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS. Rational Pharmacotherapy in Cardiology, 2018, 14, 167-175.	0.3	2
12	Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-D¢2DM). Diabetes Mellitus, 2017, 20, 403-419.	0.5	18
13	PHARMACOECONOMIC EFFECTIVENESS OF NAFTIDROFURYL IN PATIENTS WITH ISCHEMIC STROKE. Klinicist, 2017, 11, 86-92.	0.1	1
14	Pharmacoeconomic Analysis of Naftidrofuryl in Patients with Chronic Obliterating Diseases of Lower Limb Arteries. Value in Health, 2016, 19, A44.	0.1	0
15	Pharmacoeconomic Analysis of Naftidrofuryl for Ischemic Stroke Treatment. Value in Health, 2016, 19, A44-A45.	0.1	0
16	Comparative Pharmacoeconomical Analysis Of Modern Antidepressants In Monotherapy. Value in Health, 2016, 19, A186-A187.	0.1	0
17	Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of Ñ€harmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus, 2016, 19, 443-456.	0.5	23
18	Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Diabetes Mellitus, 2016, 19, 518-527.	0.5	20

DMITRY BELOUSOV

#	Article	IF	CITATIONS
19	Comparative pharmacoepidemiological study of antihyperglycemic drugs utilization by patients with type 2 diabetes mellitus in Moscow. Diabetes Mellitus, 2016, 19, 260-272.	0.5	О
20	Budget Impact Analysis of Pramipexole Extended Release Monotherapy In Early Parkinson'S Disease. Value in Health, 2015, 18, A752-A753.	0.1	1
21	Cost-Effectiveness Analysis of Pramipexole Extended Release Monotherapy In Early Parkinson`S Disease. Value in Health, 2015, 18, A757.	0.1	Ο
22	Budget Impact of Perampanel for The Treatment of Patients With Partial-Onset Seizures (Pos) In Russia. Value in Health, 2015, 18, A751.	0.1	0
23	Pharmacoeconomic Analysis Of Afatinib As 1st-Line Treatment Of Metastatic Non-Small Cell Lung Cancer With Del19 Mutation Of Egfr Gene. Value in Health, 2015, 18, A458-A459.	0.1	Ο
24	Cost-Utility Analysis of Pramipexole Extended Release Monotherapy In Early Parkinson`S Disease. Value in Health, 2015, 18, A758-A759.	0.1	0
25	RESULTS OF PHARMACOEPIDEMIOLOGIC STUDY OF ARTERIAL HYPERTENSION PIFAGOR IV: PHYSICIANS COMPLIANCE. Russian Journal of Cardiology, 2015, , 59-66.	0.4	19
26	Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow. Diabetes Mellitus, 2015, 18, 32-46.	0.5	5
27	Analysis of epidemiological indices of type 2 diabetes mellitus in the adult population of Moscow. Diabetes Mellitus, 2014, 17, 5-16.	0.5	5
28	Pharmacoeconomic Analysis of Diferent Anti-Parkinsonian Drugs Used in Monopherapy During Early Stages of Parkinson Disease. Value in Health, 2013, 16, A623.	0.1	0
29	PCV59 Cost-Effectiveness of Dabigatran Etexilate Versus Apirin Plus Clopidogrel Combination in Stroke Prevention in Atrial Fibrillation (SPAF): Russian Payer Perspective. Value in Health, 2012, 15, A122.	0.1	Ο
30	PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2012, 8, 37-44.	0.3	1
31	ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2011, 7, 561-566.	0.3	Ο
32	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus. Diabetes Mellitus, 2009, 12, 63-66.	0.5	0